GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Forward PE Ratio

Silence Therapeutics (Silence Therapeutics) Forward PE Ratio : 0.00 (As of Jun. 01, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Forward PE Ratio?

Silence Therapeutics's Forward PE Ratio for today is 0.00.

Silence Therapeutics's PE Ratio without NRI for today is 0.00.

Silence Therapeutics's PE Ratio for today is 0.00.


Silence Therapeutics Forward PE Ratio Historical Data

The historical data trend for Silence Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Forward PE Ratio Chart

Silence Therapeutics Annual Data
Trend
Forward PE Ratio

Silence Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Silence Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Silence Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Forward PE Ratio falls into.



Silence Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Silence Therapeutics  (OTCPK:SLNCF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Silence Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.